Organon/$OGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Organon
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Ticker
$OGN
Sector
Primary listing
NYSE
Employees
10,000
Headquarters
Website
Organon Metrics
BasicAdvanced
$3.5bn
14.07
$0.94
0.64
$0.08
0.60%
Price and volume
Market cap
$3.5bn
Beta
0.64
52-week high
$13.39
52-week low
$5.69
Average daily volume
14m
Dividend rate
$0.08
Financial strength
Total debt to equity
1,170.213
Interest coverage (TTM)
2.51%
Profitability
EBITDA (TTM)
1,601.25
Gross margin (TTM)
53.87%
Net profit margin (TTM)
3.99%
Operating margin (TTM)
20.02%
Effective tax rate (TTM)
54.19%
Revenue per employee (TTM)
$620,000
Management effectiveness
Valuation
Price to earnings (TTM)
14.069
Price to revenue (TTM)
0.56
Price to book
4.59
Price to tangible book (TTM)
-0.76
Dividend yield (TTM)
0.60%
Forward dividend yield
0.60%
Growth
Revenue change (TTM)
-2.08%
Earnings per share change (TTM)
-67.25%
3-year revenue growth (CAGR)
0.10%
3-year earnings per share growth (CAGR)
-31.41%
3-year dividend per share growth (CAGR)
-62.30%
What the Analysts think about Organon
Analyst ratings (Buy, Hold, Sell) for Organon stock.
Organon Financial Performance
Revenues and expenses
Organon Earnings Performance
Company profitability
Organon News
AllArticlesVideos
Organon Reports Results for the First Quarter Ended March 31, 2026
Business Wire·5 days ago
Organon Cancels First Quarter Earnings Call
Business Wire·6 days ago
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN
Business Wire·7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Organon stock?
Organon (OGN) has a market cap of $3.5B as of May 05, 2026.
What is the P/E ratio for Organon stock?
The price to earnings (P/E) ratio for Organon (OGN) stock is 14.07 as of May 05, 2026.
Does Organon stock pay dividends?
Yes, the Organon (OGN) stock pays dividends to shareholders. As of May 05, 2026, the dividend rate is $0.08 and the yield is 0.6%. Organon has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Organon dividend payment date?
The next Organon (OGN) dividend payment is scheduled for June 11, 2026.
What is the beta indicator for Organon?
Organon (OGN) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.